Make Informed Investment Decisions with Affordable Access to Experts
Preparing for MGL-3196 Data and Discussing the NASH Pipeline, with an additional focus on NGM282 and VK2809Ticker(s): MDGL, NGM Bio, VKTX
Name: Dr Stephen Harrison - MD
Institution: University of Oxford (UK) and Pinnacle Clinical Research (US)
- Medical Director of Pinnacle Clinical Research.
- Leading authority on liver diseases.
- Peer-reviewer for over 20 medical journals and internationally known for studies in hepatitis C and non-alcoholic fatty liver disease with over 150 peer reviewed publications in these fields.
Please describe your background and familiarity with MGL-3196.Added By: joe_mccann
What are the links between liver fat and NASH? And what kind of percent fat reduction do you think is meaningful?Added By: joe_mccann
Please give us your opinion on the three clinical candidates: MGL-3196, Viking 2809 and the NGM282.
Judging from what you saw in the 12 week data for MGL-3196, how that would correspond to 36 week data, and what are the major risks of those next 24 weeks?
What percentage of the patients with NASH are also diabetic, and do those patients have a worse prognosis?Added By: c_admin
What can biopsies tell you that we can't tell from MRI based methods, ultrasound and other markers like LiverMultiScan?Added By: c_admin
What do you think about FGF-19’s mechanism of action, as a potential oncogenic target?
Can you make a class comparison of CYMABAY or generally what you thought about their data at EASL and the class of PPAR?Added By: c_admin
What do you think about the thyroid hormone receptor beta as a target? What percent of the patients with hypothyroidism will have benefit?Added By: c_admin
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.